Diffuse gliomas are the most common primary brain tumor in adults, affecting about 20,000 people in the US each year [1]. Epileptic seizures often develop in patients with gliomas (40%–70%) and approximately 30% are pharmaco-resistant even after glioma resection [2,3]. There is an abundance of literature supporting the association between tumor grade and histopathology and glioma-related epilepsy [3,4]. However, recent studies suggest that epileptogenesis is also influenced by tumor molecular genetic markers [4–7].
26
MAY
MAY
0